1 2004 Vol: 26(3). DOI: 10.1590/S1516-44462004000300009

O eixo hipotálamo-pituitária-adrenal, a função dos receptores de glicocorticóides e sua importância na depressão

OBJECTIVES: Changes in the hypothalamic-pituitary-adrenocortical (HPA) system are characteristic of depression. Because the effects of glucocorticoids are mediated by intracellular receptors including, most notably, the glucocorticoid receptor (GR), several studies have examined the number and/or function of GRs in depressed patients. METHODS: Review scientific evidences have consistently demonstrated that GR function is impaired in major depression, resulting in reduced GR-mediated negative feedback on the HPA axis and increased production and secretion of CRF in various brain regions postulated to be involved in the causality of depression. RESULTS: This article summarizes the literature on GR in depression and on the impact of antidepressants on the GR in clinical and preclinical studies, and supports the concept that impaired GR signalling is a key mechanism in the pathogenesis of depression, in the absence of clear evidence of decreased GR expression. The data also indicate that antidepressants have direct effects on the GR, leading to enhanced GR function and increased GR expression. Although the effects of antidepressants on glucocorticoid hormones and their receptors are relevant for the therapeutic action of these drugs, the molecular mechanisms underlying these effects are unclear. We propose that antidepressants in humans could inhibit steroid transporters localised on the blood-brain barrier and in neurones, like the multidrug resistance p-glycoprotein, and thus increase the access of cortisol to the brain and the glucocorticoid-mediated negative feedback on the HPA axis. CONCLUSION: Enhanced cortisol action in the brain might prove to be a successful approach to maximise therapeutic antidepressant effects. Hypotheses regarding the mechanism of these receptor changes involve non-steroid compounds that regulate GR function via second messenger pathways. Research in this field will lead to new insights into the pathophysiology and treatment of affective disorders.

Mentions
Figures
Figure 1 Figure 2 Figure 3 Figure 4
Altmetric
References
  1. Checkley S. The neuroendocrinology of depression and chronic stress. Br Med Bull.52(3) , 597-617 (1996) .
  2. Nemeroff CB. The corticotropin-releasing factor (CRF hypothesis of depression: new findings and new directions. Mol Psychiatry.1(4):336 , (1996) .
  3. Juruena MF, Cleare AJ, Bauer ME, Pariante CM. Molecular mechanism of GR sensitivity and relevance for affective disorders for special issue Acta Neuropsychiatrica.15(3) , 354-67 (2003) .
  4. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev.19(3) , 269-301 (1998) .
  5. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry.49(5) , 391-404 (2001) .
  6. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestation of depression. Relation to the neurobiology of stress. N Engl J Med.319(7):;.Erratum in: N Engl J Med. 1988;319921):1428 , 413-20 (1988) .
  7. Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 200253(4) , 865-71 .
  8. Kellner M, Yehuda R. Do panic disorder and posttraumatic stress disorder share a common psychoneuroendocrinology? Psychoneuroendocrinology.24(5) , 485-504 (1999) .
  9. Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry.158(4) , 641-3 (2001) .
  10. Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, et al. Hypothalamo -pituitary-adrenal axis function in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab.86(8) , 3545-54 (2001) .
  11. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry.7(3) , 254-75 (2002) .
  12. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology.23(5) , 477-501 (2000) .
  13. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry.177 , 390-5 (2000) .
  14. Owens MJ, Nemeroff CB. The ole of HLC in the pathophysiology of affective disorders. New York: John Wiley & Sons; (Laboratory and Clinical Studies, 172) , (1993) .
  15. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitaryadrenocortical regulation. Endocr Rev.17 , 187-205 (1996) .
  16. Axelson DA, Doraiswamy PM, Boyko OB, Rodrigo EP, McDonald WM, Ritchie JC, et al. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res.44(1) , 63-70 (1992) .
  17. Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, et al. Pituitary volume in psychosis. Br J Psychiatry.185 , 5-10 (2004) .
  18. Heuser IJ, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, et al. Cerebrospinal fluid concentrations of corticotropin-releasing-hormone vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress Anxiety.8(2) , 71-9 (1998) .
  19. Carroll J. Clinical applications of the dexamethasone suppression test for endogenous depression. Pharmacopsychiatria.15(1) , 19-24 (1982) .
  20. Vale W, Spiess I, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and betaendorphin. Science.213(4514) , 1394-7 (1981) .
  21. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, et al. Responses to corticotrophin-releasing hormone in the hyporcortisolism of depression and Cushing's disease. N Engl J Med.314(21) , 1329-35 (1986) .
  22. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Muller OA, Stalla GK. Human corticotropinreleasing hormone (HLC) in patients with depression, alcoholism and panic disorder. Biol Psychiatry.21(7) , 601-11 (1986) .
  23. von Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone- hHLC challenge in patients with depression. J Neuroendocrinol.1 , 485-8 (1989) .
  24. von Bardeleben U, Holsboer F. Effect of age upon the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. Biol Psychiatry.29(10) , 1042-50 (1991) .
  25. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res.28(4) , 341-56 (1994) .
  26. Meijer OC, de Lange ECM, Breimer DD, de Boer AC, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdrlAP-glycoprotein knockout mice. Endocrinology.139(4) , 1789-93 (1998) .
  27. von Bardeleben U, Holsboer F, Stalla GK, Muller OA. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci.37(17) , 1613-9 (1985) .
  28. Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams textbook of endocrinology, 9th ed. Philadelphia: W.B. Saunders p , 517-664 (1998) .
  29. Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, et al. A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol Psychiatry.51(11) , 922-30 (2002) .
  30. Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, de Boer AG, et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology.142(6) , 2686-94 (2001) .
  31. Nemeroff CB, Widerlov E, Bissette C, Walleus H, Karlsson I, EkLund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science.226(4680) , 1342-4 (1984) .
  32. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin- releasing factor (HLC) binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry.45(6) , 377-9 (1988) .
  33. Raadsheer FC, Hoogendijk WIG, Stam FC, Tilders FHJ, Swaab DF. Increased numbers of corticotropinreleasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology.60 , 436-44 (1994) .
  34. de Bellis MD, Gold PW, Geracioti TD Jr, Listwak SI, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropinreleasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry.150(4) , 656-7 (1993) .
  35. Miller AH, Spencer RL, Pulera M, Kang S, McEwen BS, Stein M. Adrenal steroid receptor activation in rat brain and pituitary following dexamethasone: Implications for the dexamethasone suppression test. Biol Psychiatry.32(10) , 850-69 (1992) .
  36. Young EA, Haskett RF, Murphy.Weinberg V, Watson SI, Akil H. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry.48(8) , 693-9 (1991) .
  37. Glover V, O'Connor TG. Effects of antenatal stress and anxiety: Implications for development and psychiatry Br J Psychiatry.180 , 389-91 (2002) .
  38. Ribeiro SCM, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry.150(11) , 1618-29 (1993) .
  39. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry.156(6) , 949-51 (1999) .
  40. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression a prospective study. J Psychiatr Res.35(2) , 83-94 (2001) .
  41. Sapolsky RM. Glucocorticoid toxicity in the hippocampus: reversal by supplementation with brain fuels. J Neurosci.6(8) , 2240-4 (1986) .
  42. McEwen BS, Seeman T. Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load. Ann N Y Acad Sci.896 , 30-47 (1999) .
  43. Sapolsky RM, Romero M, Munck AU. How do glucocorticoids influence stress responses? integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev.21(1) , 55-89 (2000) .
  44. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry.160(9) , 1554-65 (2003) .
  45. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res.886:172-89 , 1-2 (2000) .
  46. Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology.139(6) , 2718-26 (1998) .
  47. Pratt WB. The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem.268(29) , 21455-8 (1993) .
  48. Guiochon-Mantel A, Delabre K, Lescop P, Milgrom E. The Ernst Schering Poster Award. Intracellular traffic of steroid hormone receptors. J Steroid Biochem Mol Biol.56:3-9 , 1-6 (1996) .
  49. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology.117(6) , 2505-11 (1985) .
  50. Modell S, Yassouridis A, Huber I, Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology.65(3) , 216-22 (1997) .
  51. Murphy BEP. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol.39(92) , 239-44 (1991) .
  52. Gametchu B. Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis. Science.236(4800) , 456-61 (1987) .
  53. Cotter D, Pariante CM. Stress on the progress of the developmental hypothesis of schizophrenia? Br J Psychiatry.181 , 363-5 (2002) .
  54. Lopez JF, Chalmers DT, Little KI, Watson SJ. E. Bennett Research Award. Regulation of serotonin 1A, glucocorticoid and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry.43(8) , 547-73 (1998) .
  55. Bauer M, Vedhara K, Perks P, Wilcock G, Lightman S, Shanks N. Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids. J Neuroimmunol.103(1) , 84-92 (2000) .
  56. Kok F, Heijnen C, Bruijn J, Westenberg H, Van Ree J. Immunoglobulin production in vitro in major depression: a pilot study on the modulating action of endogenous cortisol. Biol Psychiatry.38(4) , 217-26 (1995) .
  57. Bauer ME, Papadopoulus A, Poon L, Perks P, Lightman SL, Checkley S, et al. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology.;28(1) , 49-65 (2003) .
  58. Bauer M, Papadopoulos A, Poon L, Perks P, Lightman S, Checkley S, Shanks N. Dexamethasone-induced effects on lymphocyte distribution and expression of adhesion molecules in treatment resistant major depression. Psychiatry Res.113:1-15 , 1-2 (2002) .
  59. Asnis GM, Haibreich U, Ryan ND, Rabinowicz H, Puig-Antich J, Nelson B, et al. The relationship of the dexamethasone suppression test (1 mg and 2 mg) to basal plasma cortisol levels in endogenous depression. Psychoneuroendocrinology.12(4) , 295-301 (1987) .
  60. Miller AH, Sastry G, Speranza Jr AJ, Lawlor BA, Mohs RC, Ryan TM, et al. Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. Am J Psychiatry.151(2) , 267-70 (1994) .
  61. Cotter P, Mulligan O, Landau S, Papadopoulos A, Lightman S, Checkley S. Vasoconstrictor response to topical beclomethasone in major depression. Psychoneuroendocrinology.27(4) , 475-87 (2002) .
  62. Maguire TM, Thakore J, Dinan TG, Hopwood S, Breen KC. Plasma sialyltransferase levels in psychiatric disorders as a possible indicator of HPA axis function. Biol Psychiatry.41(11) , 1131-6 (1997) .
  63. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depression illness as measured by computed tomography. Biol Psychiatry.41(11) , 1140-2 (1997) .
  64. Schweiger U, Deuschle M, Korner A, Lammers CH, Schmider J, Gotthard U, et al. Low lumbar bone mineral density in patients with major depression. Am J Psychiatry.151(11) , 1691-3 (1994) .
  65. Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, Gold P. Bone mineral density in women with depression. N Engl J Med.335(16) , 1176-81 (1996) .
  66. O'Malley BW, Schrader WT, Mani S, Smith C, Weigel NL, Conneely OM, et al. An alternative ligand independent pathway for activation of steroid receptors. Recent Prog Horm Res.50 , 333-47 (1995) .
  67. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function: Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol.461 , 107-16 (1999) .
  68. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, Miller AH. The proinflammatory cytokine, interleukin-1 alpha, reduces glucocorticoid receptor translocation and function. Endocrinology.140(9) , 4359-66 (1999) .
  69. Rangarajan PN, Umesono K, Evans RM. Modulation of glucocorticoid receptor function by protein kinase A Mol Endocrinol.6(9) , 1451-7 (1992) .
  70. Avissar S, Nechamkin Y, Roitman G, Schreiber G. Reduced G protein functions and immunoreactive levels in mononuclear leukocyts of patients with depression. Am J Psychiatry.154(2) , 211-7 (1997) .
  71. Shelton RC, Mainer DH, Sulser F. cAMP-dependent protein kinase activity in major depression. Am J Psychiatry.153(8) , 1037-42 (1996) .
  72. Castro M, Elliot S, Kino T, Bamberger C, Karl M, Webster E, Chrousos G. The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGC-beta): tissue levels, mechanism of action, and potential physiologic role. Mol Med.2(5) , 597-607 (1996) .
  73. Bronnegard M, Stierna P, Marcus C. Glucocorticoid resistant syndromes - molecular basis and clinical presentations. J Neuroendocrinol.8(6) , 405-15 (1996) .
  74. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, Kerwin RW. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol.13496) , 1335-43 (2001) .
  75. Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci.24(1) , 25-39 (1999) .
  76. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol.52(4) , 571-81 (1997) .
  77. Pariante CM, Pearce BD, Pisell TL, Su C, Miller AH. The steroid receptor antagonists, RU486 and RU40555, activate glucocorticoid receptor translocation and are not excreted by the steroid hormone transporter in L929 cells. J Endocrinol.169(2) , 309-20 (2001) .
  78. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci.11(4) , 265-83 (2000) .
  79. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, / et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem.267(34) , 24248-52 (1992) .
  80. de Kloet ER, Meijer OC, Vreugdenhil E, Joels M.The Yin and Yang of nuclear receptors: symposium on nuclear receptors in brain, Oegstgeest, The Netherlands, April Trends Endocrinol Metab. 2000;11(6):245-8 , 13-14 (2000) .
  81. Bourgeois S, Gruol DJ, Newby RF, Rajah FM. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol.7(5) , 840-51 (1993) .
  82. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J, Ocsovsky I, Molnar J. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res.16(1) , 209-12 (1996) .
  83. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer. 27(1) , 31-4 (1991) .
  84. Szabó D, Szabó Jr G, Ocsovszki I, Aszalos A, Molnár J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cell ex-vivo. Cancer Lett.1399(1) , 115-9 (1999) .
  85. Kralli A, Yamamoto KR. An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J Biol Chem.271(29) , 17152-6 (1996) .
  86. Marsaud V, Mercier-Bodard C, Fortin D, Le Bihan S, Renoir JM. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other p-glycoprotein ligands. J Steroid Biochem Molec Biol.66:11-25 , 1-2 (1998) .
  87. Medh RD, Lay RH, Schmidt TJ. Agonist-speciffic modulation of glucocorticoid receptor-mediated transcription by immunosuppressants. Mol Cell Endocrinol.138:11-23 , 1-2 (1998) .
  88. Przegalinski E, Budziszewska B, Siwanowicz J, Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology.32(12) , 1397-400 (1993) .
  89. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology.29(4) , 423-47 (2004) .
  90. Pariante CM, Kim RB, Makoff A, Kerwin RW. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol.139(6) , 1111-8 (2003) .
  91. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW. The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology.28(9) , 1553-61 (2003) .
  92. Lowy M, Gormley G, Reder A, Meltzer H. Immune function, glucocorticoid receptor regu lation, and depression. In: Miller, A. (Ed.), Depressive Disorders & Immunity. American Psychiatric Press, Washington, DC, 1989, pp. 107–133 , .
  93. Moalli P & Rosen S. Glucocorticoid receptors and resistance to glucocorticoids in hematologia malignancies. Leuk Lymph 15 , 363-374 (1994) .
  94. Cypcar D & Busse W. Steroid-resistant asthma. J Allergy Clin Immunol 92 , 362-372 (1993) .
  95. Hennebold J & Daynes R. Microenvironmental control of glucocorticoid functions in immune regulation. In: Rook G & Lightman S. Steroid hormones and the T-cell cytokine profile. London: Springer-Verlag. 1997 , 101-134 .
  96. Rosner W. Plasma steroid-binding proteins. Endocr Metab Clin North Amer 20 , 697-720 (1991) .
  97. Adcock I, Lane S, Brown C, Peters M, Lee T, Barnes P. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 154 , 3500-3505 (1995) .
Expand